Establishing a Risk-Based Framework to Enable Seamless Transition from Clinical Development to Commercial Launch

Conducting virtual site assessments to evaluate CMO capabilities, branding, and scalability
Applying risk-based methodologies beyond quality metrics to capture holistic launch-readiness
Integrating supplier maturity models to align with Grünenthal’s commercialization goals
Bridging clinical development and manufacturing through coordinated launch planning
Ensuring end-to-end visibility and accountability across the external supply network